Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients

Key Inclusion Criteria: Female patients with newly diagnosed, histologically confirmed, advanced (Stage III-IV) high grade epithelial ovarian cancer including high grade serious, high grade endometriod, clear cell ovarian cancer or carcinosarcoma, primary peritoneal cancer and / or fallopian-tube cancer * Patients must be aged ≥18 years of age. For patients enrolled in Japan that are aged \<20 year * All patients should be candidates for cytoreductive surgery either: upfront primary surgery OR plan to undergo chemotherapy with interval debulking surgery * Evidence of presence or absence of BRCA1/2 mutation in tumour tissue * Mandatory provision of tumour sample for centralised tBRCA testing * ECOG performance status 0-1 * Patients must have preserved organ and bone marrow function * Postmenopausal or evidence of non-childbearing status for women of childbearing potential: negative urine or serum pregnancy test Key Exclusion Criteria: Non-epithelial ovarian cancer, borderline tumors, low grade epithelial tumors or mucinous histology * Prior systemic anti-cancer therapy for ovarian cancer * Inability to determine the presence or absence of a deleterious or suspected deleterious BRCA mutation * Prior treatment with PARP inhibitor or immune mediated therapy * Planned intraperitoneal cytotoxic chemotherapy * Active or prior documented autoimmune or inflammatory disorders * Patients considered a poor medical risk due to a serious, uncontrolled intercurrent illness * Clinically…